By The Numbers: Gucci Mane's Insanely Productive Year Out Of Prison
- May 27, 2017
- 1 min read
Courtesy photo Scott Dudelson/Getty Images
Since Gucci Mane’s release from an Indiana federal penitentiary on May 26, 2016, the unstoppable Atlanta rapper has churned out an extensive body of work that would seem like an impossible feat to most. But, of course, they’re not Gucci Mane. With multiple albums, a small arsenal of videos and seemingly endless collaborations, it’s natural to wonder if the tenacious artist ever sleeps. READ MORE @ HIPHOPDX
Genuinely impressed by the depth of this article!
What's particularly notable is the growing body of evidence around cardiovascular benefits. The SELECT trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events in overweight patients without diabetes, suggesting that the benefits of GLP-1 receptor agonist therapy extend well beyond glycemic control and weight loss. Reductions in systemic inflammation, improvements in lipid profiles, and positive effects on blood pressure have all been documented. For patients who carry significant cardiometabolic risk, these incretin-based therapies represent a meaningful step forward in preventive medicine.
The mechanism behind GLP-1 therapy is fascinating from a physiological standpoint. Glucagon-like peptide-1 is an incretin hormone naturally secreted by L-cells in the small intestine in response to food intake.…